OTLK
Outlook Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$1.38-0.72%
Price as of Jul 20, 2026
OTLK financials
Outlook Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $1.4M | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $756.3K | $113.9K | $44.2K | $204.7K |
| Gross profit | $657.2K | -$113.9K | -$44.2K | -$204.7K |
| Operating expenses | $67.7M | $71.7M | $53.1M | $62.9M |
| Operating income | -$67.1M | -$71.7M | -$53.1M | -$63.1M |
| Net income | -$62.4M | -$75.4M | -$59.0M | -$66.1M |
| EBITDA | -$63.6M | -$72.1M | -$57.4M | -$64.4M |
| Basic EPS | $-1.79 | $-4.06 | $-4.72 | $-6.23 |
| Diluted EPS | $-1.79 | $-4.06 | $-4.72 | $-6.23 |
| Balance sheet | ||||
| Cash & equivalents | $8.1M | $14.9M | $23.4M | $17.4M |
| Total assets | $18.6M | $28.8M | $32.3M | $28.5M |
| Total liabilities | $50.8M | $101.9M | $46.7M | $19.8M |
| Stockholders’ equity | -$32.2M | -$73.1M | -$14.4M | $8.7M |
| Total debt | $30.2M | $29.7M | $35.6M | $11.0M |
| Net debt | $22.1M | $14.8M | $12.2M | -$6.4M |
| Cash flow | ||||
| Operating cash flow | -$51.8M | -$68.8M | -$43.0M | -$56.7M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$51.8M | -$68.8M | -$43.0M | -$56.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |